Source:http://linkedlifedata.com/resource/pubmed/id/10988118
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3 Pt 1
|
| pubmed:dateCreated |
2000-10-12
|
| pubmed:abstractText |
Six months of twice weekly directly observed isoniazid and rifam-picin treatment of latent tuberculosis (TB) infection was implemented to improve the outcome of treatment. A total of 591 infected aborigines without previous tuberculosis or treatment of latent TB infection received twice weekly isoniazid and rifampicin for 6 mo from 1992 to 1995. The outcome was compared with 403 infected aborigines without previous tuberculosis or treatment of latent TB infection who received self-administered isoniazid daily for 1 yr from 1986 to 1989. Of patients, 487 (82%) completed the twice weekly 6-mo regimen compared with 77 (19%) who completed the daily 12-mo regimen. The main reason for incomplete treatment was default. Both groups were followed over a 6-yr period. The rate of tuberculosis in the twice-weekly isoniazid and rifampicin-treated patients was 0.9/1,000 patient-years compared with 9/1,000 patient-years in the daily isoniazid-treated patients. The rate of side effects was higher for directly observed treatment patients, 136/1,000 patient-years of drugs, compared with 39/ 1,000 patient-years for self-administered treatment patients. Life-threatening side effects such as skin allergic reactions and hepatitis were the same in both groups. A regimen of 52 doses of directly observed twice weekly isoniazid and rifampicin is an effective and well-tolerated regimen to improve the outcome of the treatment of latent tuberculosis infection in a population with a high rate of default with daily self-administered isoniazid.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
162
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
989-93
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10988118-Adolescent,
pubmed-meshheading:10988118-Adult,
pubmed-meshheading:10988118-American Native Continental Ancestry Group,
pubmed-meshheading:10988118-Antitubercular Agents,
pubmed-meshheading:10988118-Child,
pubmed-meshheading:10988118-Child, Preschool,
pubmed-meshheading:10988118-Dose-Response Relationship, Drug,
pubmed-meshheading:10988118-Drug Administration Schedule,
pubmed-meshheading:10988118-Drug Therapy, Combination,
pubmed-meshheading:10988118-Female,
pubmed-meshheading:10988118-Follow-Up Studies,
pubmed-meshheading:10988118-Humans,
pubmed-meshheading:10988118-Infant,
pubmed-meshheading:10988118-Isoniazid,
pubmed-meshheading:10988118-Male,
pubmed-meshheading:10988118-Rifampin,
pubmed-meshheading:10988118-Saskatchewan,
pubmed-meshheading:10988118-Tuberculosis, Pulmonary
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines.
|
| pubmed:affiliation |
Division of Tuberculosis Control, Department of Medicine, Research Center for the Elimination of Tuberculosis, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
|
| pubmed:publicationType |
Journal Article
|